We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+2.33%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$12B
AUM Growth
-$622M
Cap. Flow
-$298M
Cap. Flow %
-2.48%
Top 10 Hldgs %
21.36%
Holding
837
New
28
Increased
81
Reduced
101
Closed
16

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$5.83K
2
RY icon
Royal Bank of Canada
RY
+$4.09K
3
RIO icon
Rio Tinto
RIO
+$3.61K
4
AMGN icon
Amgen
AMGN
+$3.58K
5
ARW icon
Arrow Electronics
ARW
+$3.22K

Top Sells

Rank Stock Value
1
EDU icon
New Oriental
EDU
+$35.3M
2
TIF
Tiffany & Co.
TIF
+$27.7M
3
VRNS icon
Varonis Systems
VRNS
+$17.6M
4
OSB
Norbord Inc.
OSB
+$16.7M
5
QEP
QEP RESOURCES, INC.
QEP
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 34.23%
2 Technology 22.73%
3 Consumer Discretionary 9.47%
4 Financials 7.93%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MUFG icon
776
Mitsubishi UFJ Financial
MUFG
$253B
$1K ﹤0.01%
+230
New +$1.19K
SPRY icon
777
ARS Pharmaceuticals
SPRY
$563M
$1K ﹤0.01%
+13
New +$615
VOD icon
778
Vodafone
VOD
$37.7B
$1K ﹤0.01%
48
-1
-2% -$18
ZLAB icon
779
Zai Lab
ZLAB
$2.1B
$1K ﹤0.01%
+5
New +$774
HARP
780
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1K ﹤0.01%
+3
New +$601
RDS.A
781
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$1K ﹤0.01%
+24
New +$966
ADCT icon
782
ADC Therapeutics
ADCT
$141M
$0 ﹤0.01%
8
-1
-11% -$29
BHP icon
783
BHP
BHP
$213B
– –
-82
Closed -$5K
CRSP icon
784
CRISPR Therapeutics
CRSP
$4.68B
– –
-3
Closed –
EPIX
785
DELISTED
ESSA Pharma
EPIX
$0 ﹤0.01%
+17
New +$395
KYMR icon
786
Kymera Therapeutics
KYMR
$8.73B
$0 ﹤0.01%
+7
New +$421
LUMN icon
787
Lumen
LUMN
$6.38B
– –
-64,974
Closed -$634K
MFG icon
788
Mizuho Financial
MFG
$123B
$0 ﹤0.01%
+18
New +$52
NGNE icon
789
Neurogene
NGNE
$663M
$0 ﹤0.01%
+2
New +$511
NRIX icon
790
Nurix Therapeutics
NRIX
$2.51B
$0 ﹤0.01%
+13
New +$492
NVCR icon
791
NovoCure
NVCR
$1.89B
$0 ﹤0.01%
2
-2
-50% -$316
OLMA icon
792
Olema Pharmaceuticals
OLMA
$1.01B
$0 ﹤0.01%
+13
New +$557
RLAY icon
793
Relay Therapeutics
RLAY
$3.99B
$0 ﹤0.01%
+11
New +$477
RVMD icon
794
Revolution Medicines
RVMD
$39.1B
$0 ﹤0.01%
+10
New +$448
SMFG icon
795
Sumitomo Mitsui Financial
SMFG
$163B
$0 ﹤0.01%
+6
New +$42
ZNTL icon
796
Zentalis Pharmaceuticals
ZNTL
$329M
$0 ﹤0.01%
+11
New +$474
BCEL
797
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$0 ﹤0.01%
+25
New +$406
JNCE
798
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$0 ﹤0.01%
+5
New +$55
TRIL
799
DELISTED
Trillium Therapeutics Inc.
TRIL
$0 ﹤0.01%
+42
New +$519
UROV
800
DELISTED
Urovant Sciences Ltd.
UROV
– –
-167,787
Closed -$2.71M
29 30 31
32
33

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2021 Portfolio in Review

As of Q1 2021, Candriam SCA held 837 positions worth $12B, down 4.9% from $12.6B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Candriam SCA's Q1 2021 filing shows 28 new, 81 increased, 101 reduced and 16 closed positions. Its largest new stake was Arrow Electronics: 31 shares worth $3K. The largest sale was New Oriental, an estimated $35.3M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 34% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Candriam SCA's largest Q1 2021 buy was Arrow Electronics: 31 shares worth $3K.
  • Candriam SCA added most to AstraZeneca in Q1 2021, an estimated $5.83K increase.
  • Candriam SCA's biggest Q1 2021 reduction was New Oriental, cutting an estimated $35.3M.
  • Candriam SCA fully exited Tiffany & Co. in Q1 2021, selling an estimated $27.7M.
  • Candriam SCA's ten largest holdings make up 21% of its $12B portfolio in Q1 2021.
  • Candriam SCA opened 28 new positions and closed 16 in Q1 2021.
  • Candriam SCA's portfolio value fell 4.9% quarter-over-quarter to $12B.

Based on Candriam SCA's 13F filing for Q1 2021, filed 29 Apr 2021.